Movement Alert｜BeiGene Rises 3.05% in Regular Trading, Tevimbra Esophageal Cancer Application Accepted by FDA

Market Focus10:14

On June 18, BeiGene rose 3.05% in regular trading, trading at 162.5 HKD/share, with turnover of HKD 146 million.

On the news front, BeiGene recently announced that the U.S. Food and Drug Administration has accepted its supplemental Biologics License Application for Tevimbra (tislelizumab) targeting esophageal squamous cell carcinoma, marking a key milestone in the company's overseas indication expansion for its core PD-1 product. Additionally, the company's Q1 net profit attributable to shareholders surged 1,801.3% year-over-year, with gross margin approaching 90%, reflecting sustained fundamental improvement.

The broader biotechnology sector rallied in tandem today, with AKESO up 5.48%, SKB BIO up 3.52%, 3SBIO up 2.55%, INNOVENT BIO up 2.54%, and REMEGEN up 2.52%, providing sector-wide support to BeiGene as a heavyweight constituent.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191609722?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 10:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191609722","market":"hk","top_or_hot":-1,"title":"Movement Alert｜BeiGene Rises 3.05% in Regular Trading, Tevimbra Esophageal Cancer Application Accepted by FDA","media":"Market Focus","content":"<p><p>On June 18, BeiGene rose 3.05% in regular trading, trading at 162.5 HKD/share, with turnover of HKD 146 million.</p><p>On the news front, BeiGene recently announced that the U.S. Food and Drug Administration has accepted its supplemental Biologics License Application for Tevimbra (tislelizumab) targeting esophageal squamous cell carcinoma, marking a key milestone in the company's overseas indication expansion for its core PD-1 product. Additionally, the company's Q1 net profit attributable to shareholders surged 1,801.3% year-over-year, with gross margin approaching 90%, reflecting sustained fundamental improvement.</p><p>The broader biotechnology sector rallied in tandem today, with AKESO up 5.48%, SKB BIO up 3.52%, 3SBIO up 2.55%, INNOVENT BIO up 2.54%, and REMEGEN up 2.52%, providing sector-wide support to BeiGene as a heavyweight constituent.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BeiGene Rises 3.05% in Regular Trading, Tevimbra Esophageal Cancer Application Accepted by FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BeiGene Rises 3.05% in Regular Trading, Tevimbra Esophageal Cancer Application Accepted by FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-18 10:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 18, BeiGene rose 3.05% in regular trading, trading at 162.5 HKD/share, with turnover of HKD 146 million.</p><p>On the news front, BeiGene recently announced that the U.S. Food and Drug Administration has accepted its supplemental Biologics License Application for Tevimbra (tislelizumab) targeting esophageal squamous cell carcinoma, marking a key milestone in the company's overseas indication expansion for its core PD-1 product. Additionally, the company's Q1 net profit attributable to shareholders surged 1,801.3% year-over-year, with gross margin approaching 90%, reflecting sustained fundamental improvement.</p><p>The broader biotechnology sector rallied in tandem today, with AKESO up 5.48%, SKB BIO up 3.52%, 3SBIO up 2.55%, INNOVENT BIO up 2.54%, and REMEGEN up 2.52%, providing sector-wide support to BeiGene as a heavyweight constituent.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1191609722","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191609722","pubTimestamp":1781748894,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 18, BeiGene rose 3.05% in regular trading, trading at 162.5 HKD/share, with turnover of HKD 146 million.On the news front, BeiGene recently announced that the U.S. Food and Drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"动静快讯|百济神州常规交易涨3.05%Tevimbra食管癌申请获FDA受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"On June 18, BeiGene rose 3.05% in regular trading, trading at 162.5 HKD/share, with turnover of HKD 146 million.On the news front, BeiGene recently announced that the U.S. Food and Drug Administration has accepted its supplemental Biologics License Application for Tevimbra (tislelizumab) targeting esophageal squamous cell carcinoma, marking a key milestone in the company's overseas indication expansion for its core PD-1 product. Additionally, the company's Q1 net profit attributable to shareholders surged 1,801.3% year-over-year, with gross margin approaching 90%, reflecting sustained fundamental improvement.The broader biotechnology sector rallied in tandem today, with AKESO up 5.48%, SKB BIO up 3.52%, 3SBIO up 2.55%, INNOVENT BIO up 2.54%, and REMEGEN up 2.52%, providing sector-wide support to BeiGene as a heavyweight constituent.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191609722","isCrawlerRequest":true}